terminate a license agreement it entered into in 2011 with  AVEO Pharmaceuticals, Inc. (“AVEO”) of the U.S. for the  development and commercialization of tivozanib (generic  name/development code: ASP4130), an inhibitor of all  three vascular endothelial growth factor receptors 1, 2 and  3, which had been under joint development. The Company  took the decision for strategic reasons, based on the clini- cal status of the three indications studied (renal cell carci- noma, colorectal cancer and breast cancer). The  termination of the license agreement will be effective  August 11, 2014, at which time tivozanib rights will be  returned to AVEO. In June 2013, the Company concluded a collaboration  agreement with Cytokinetics, Inc. of the U.S., focusing on  the research, development and commercialization of skel- etal muscle activators. The primary objective of the collabo- ration is to advance novel therapies for diseases and  medical conditions associated with muscle weakness. The  two parties will jointly conduct research and development  in the area of skeletal muscle activation. In March 2013, the Company exercised its right to  terminate the worldwide license agreement with Ambit  Biosciences Corporation of the U.S. concluded in 2009 for  the joint development and commercialization of FLT3  kinase inhibitors including quizartinib (generic name/code  name: AC220). The agreement, which the Company exer- cised its right to terminate for strategic reasons, came to  an end on September 3, 2013. In October 2013, the Company entered into an exclusive  collaboration agreement with Mitokyne, Inc. of the U.S. for  joint research and development in the area of mitochondria- related diseases. Under the agreement, the two companies  are jointly conducting research and development to find  breakthrough treatments in this therapeutic area, in which  an effective therapy is yet to be established. Also in February 2014, the Company amended a license  agreement, which was entered into in February 2010, on  isavuconazole (generic name), an azole antifungal agent  under joint development with Basilea Pharmaceutica Ltd.  of Switzerland, for strategic reasons. Based on the amend- ment, the territories subject to the license agreement have  been changed from “worldwide except Japan” to “the  U.S. and Canada,” and the Company is now responsible  for applications for approval and has exclusive full respon- sibility for the manufacture and sale of isavuconazole in  both countries. In March 2014, the Company entered into a collabora- tion agreement with Daiichi Sankyo Company, Limited to  form a compound library sharing partnership for approxi- mately 400,000 selected compounds from the whole  library of each company. The collaboration enables each  party to promote innovative new medicine research and development. In December 2013, the Company entered into a joint  research agreement with Immuno-Biological Laboratories  Co., Ltd. regarding pharmaceutical applications of recom- binant human proteins made using transgenic silkworms.  Under the agreement, the two companies are jointly con- ducting research and development with respect to a useful  recombinant human protein made using transgenic silk- worms. This includes examining and evaluating the produc- tion method and looking into the possibility of developing  the protein as medicine. In January 2014, the Company entered into an agree- ment for a strategic alliance with ClearPath Development  Company (“ClearPath”) of the U.S. to form a portfolio of  vaccines targeting infectious diseases. Through this   alliance, the Company will fund the development of a   virosome vaccine technology for respiratory syncytial virus,  licensed from Mymetics Corporation of the U.S., by RSV  Corporation, a company managed and operated by  ClearPath. The alliance will help the Company to build up  its vaccine portfolio. In February 2014, the Company exercised its right to  In August 2013, the Company and MSD K.K. entered into  a co-promotion agreement in Japan for Suglat. Under the  agreement, the manufacture and sale of the drug will be  carried out by the Company, while the Company, MSD,  and Kotobuki Pharmaceutical Co., Ltd. will co-promote it. In July 2013, the Company established a sales affiliate  in Singapore, Astellas Pharma Singapore Pte. Ltd. The  business started operations in October 2013. Astellas  Pharma Singapore will mainly commercialize Astellas’  global products through its own sales force in Singapore  and supervise the sales of such products through a Contract  97 Annual Report 2014 _  Astellas Pharma Inc.  Financial Section Commercial Partnerships and Measures to  Strengthen Business Capabilities